POTENTIAL OF ANTI-INFLAMMATORY THERAPY IN SCHIZOPHRENIA: CURRENT APPROACHES AND PROSPECTS: LITERATURE REVIEW
DOI:
https://doi.org/10.22159/ijap.2026v18i2.57215Keywords:
Neuroinflammation, Cytokines, Immune processes, Interleukins, Cognitive impairments, Microglial activation, NeurotransmittersAbstract
The purpose of this study is to determine the effectiveness of modern anti-inflammatory treatments for schizophrenia and identify the most promising therapeutic strategies. The data on inflammatory processes are systematised based on the analysis of genetic, immunological, and neuroimaging studies, a comparative analysis of anti-inflammatory drugs is performed, and criteria for their effectiveness in various clinical manifestations of the disease are determined. The systematisation of scientific data indicates the existence of a relationship between inflammatory markers, the severity of clinical manifestations of schizophrenia, and resistance to antipsychotics. An analysis of the literature allowed us to identify the main biomarkers of neuroinflammation, which are potential predictors of the effectiveness of antipsychotic therapy. Published studies indicate potential benefits of adjunctive anti-inflammatory therapy in certain patient subgroups; however, the strength of the available evidence varies considerably, and high-quality randomized trials confirming these findings are currently lacking. The study suggests the need to integrate anti-inflammatory approaches into standard treatment protocols for schizophrenia, especially for patients with high levels of inflammatory markers, and opens up prospects for the development of personalised therapeutic strategies based on the individual inflammatory profile of the patient.
References
1. Fond G, Mallet J, Urbach M, Benros ME, Berk M, Billeci M. Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids hormonal therapies and anti-inflammatory drugs. BMJ Ment Health. 2023;26(1):e300771. doi: 10.1136/bmjment-2023-300771, PMID 37852631.
2. Mongan D, Ramesar M, Focking M, Cannon M, Cotter D. Role of inflammation in the pathogenesis of schizophrenia: a review of the evidence proposed mechanisms and implications for treatment. Early Interv Psychiatry. 2020;14(4):385-97. doi: 10.1111/eip.12859, PMID 31368253.
3. Jeppesen R, Christensen RH, Pedersen EM, Nordentoft M, Hjorthoj C, Kohler-Forsberg O. Efficacy and safety of anti-inflammatory agents in treatment of psychotic disorders a comprehensive systematic review and meta-analysis. Brain Behav Immun. 2020;90:364-80. doi: 10.1016/j.bbi.2020.08.028, PMID 32890697.
4. Bishop JR, Zhang L, Lizano P. Inflammation subtypes and translating inflammation-related genetic findings in schizophrenia and related psychoses: a perspective on pathways for treatment stratification and novel therapies. Harv Rev Psychiatry. 2022;30(1):59-70. doi: 10.1097/HRP.0000000000000321, PMID 34995036.
5. Chen W, Gou M, Wang L, Li N, Li W, Tong J. Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia. Eur Neuropsychopharmacol. 2023;72:18-29. doi: 10.1016/j.euroneuro.2023.03.014, PMID 37058967.
6. Patel S, Keating BA, Dale RC. Anti-inflammatory properties of commonly used psychiatric drugs. Front Neurosci. 2023;16:1039379. doi: 10.3389/fnins.2022.1039379, PMID 36704001.
7. Patlola SR, Donohoe G, McKernan DP. Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: a systematic review and meta-analysis. J Psychiatr Res. 2023;160:126-36. doi: 10.1016/j.jpsychires.2023.01.042, PMID 36804109.
8. De Simone G, Mazza B, Vellucci L, Barone A, Ciccarelli M, De Bartolomeis A. Schizophrenia synaptic pathology and antipsychotic treatment in the framework of oxidative and mitochondrial dysfunction: translational highlights for the clinics and treatment. Antioxidants (Basel). 2023;12(4):975. doi: 10.3390/antiox12040975, PMID 37107350.
9. Mills E. Living with mental illness: a study in East London. Abingdon: Routledge; 2023. doi: 10.4324/9781003425175.
10. Panizzutti B, Skvarc D, Lin S, Croce S, Meehan A, Bortolasci CC. Minocycline as treatment for psychiatric and neurological conditions: a systematic review and meta-analysis. Int J Mol Sci. 2023;24(6):5250. doi: 10.3390/ijms24065250, PMID 36982324.
11. McIntyre RS, Berk M, Brietzke E, Goldstein BI, Lopez Jaramillo C, Kessing LV. Bipolar disorders. Lancet. 2020;396(10265):1841-56. doi: 10.1016/S0140-6736(20)31544-0, PMID 33278937.
12. Limongi R, Jeon P, Mackinley M, Das T, Dempster K, Theberge J. Glutamate and dysconnection in the salience network: neurochemical effective connectivity and computational evidence in schizophrenia. Biol Psychiatry. 2020;88(3):273-81. doi: 10.1016/j.biopsych.2020.01.021, PMID 32312577.
13. Alonso Sanchez MF, Limongi R, Gati J, Palaniyappan L. Language network self-inhibition and semantic similarity in first-episode schizophrenia: a computational-linguistic and effective connectivity approach. Schizophr Res. 2023;259:97-103. doi: 10.1016/j.schres.2022.04.007, PMID 35568676.
14. Crellin NE, Priebe S, Morant N, Lewis G, Freemantle N, Johnson S. An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders. BMC Psychiatry. 2022;22(1):185. doi: 10.1186/s12888-022-03822-5, PMID 35291964.
15. Dickson H, Hedges EP, Ma SY, Cullen AE, MacCabe JH, Kempton MJ. Academic achievement and schizophrenia: a systematic meta-analysis. Psychol Med. 2020;50(12):1949-65. doi: 10.1017/S0033291720002354, PMID 32684198.
16. Fond G, Lancon C, Korchia T, Auquier P, Boyer L. The role of inflammation in the treatment of schizophrenia. Front Psychiatry. 2020;11:160. doi: 10.3389/fpsyt.2020.00160, PMID 32256401.
17. Williams JA, Burgess S, Suckling J, Lalousis PA, Batool F, Griffiths SL. Inflammation and brain structure in schizophrenia and other neuropsychiatric disorders: a Mendelian randomization study. JAMA Psychiatry. 2022;79(5):498-507. doi: 10.1001/jamapsychiatry.2022.0407, PMID 35353173.
18. Ansari Z, Pawar S, Seetharaman R. Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing? Postgrad Med. 2022;134(2):187-99. doi: 10.1080/00325481.2021.2006514, PMID 34766870.
19. Dawidowski B, Gorniak A, Podwalski P, Lebiecka Z, Misiak B, Samochowiec J. The role of cytokines in the pathogenesis of schizophrenia. J Clin Med. 2021;10(17):3849. doi: 10.3390/jcm10173849, PMID 34501305.
20. Reale M, Costantini E, Greig NH. Cytokine imbalance in schizophrenia from research to clinic: potential implications for treatment. Front Psychiatry. 2021;12:536257. doi: 10.3389/fpsyt.2021.536257, PMID 33746786.
21. Comer AL, Carrier M, Tremblay ME, Cruz Martin A. The inflamed brain in schizophrenia: the convergence of genetic and environmental risk factors that lead to uncontrolled neuroinflammation. Front Cell Neurosci. 2020;14:274. doi: 10.3389/fncel.2020.00274, PMID 33061891.
22. Siskind D, Orr S, Sinha S, Yu O, Brijball B, Warren N. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115-20. doi: 10.1192/bjp.2021.61, PMID 35049446.
23. Juckel G, Freund N. Microglia and microbiome in schizophrenia: can immunomodulation improve symptoms? J Neural Transm (Vienna). 2023;130(9):1187-93. doi: 10.1007/s00702-023-02605-w, PMID 36810627.
24. Murphy CE, Walker AK, O’Donnell M, Galletly C, Lloyd AR, Liu D. Peripheral NF-κB dysregulation in people with schizophrenia drives inflammation: putative anti-inflammatory functions of NF-κB kinases. Transl Psychiatry. 2022;12(1):21. doi: 10.1038/s41398-021-01764-2, PMID 35027554.
25. Gangadin SS, Enthoven AD, Van Beveren NJ, Laman JD, Sommer IE. Immune dysfunction in schizophrenia spectrum disorders. Annu Rev Clin Psychol. 2024;20(1):229-57. doi: 10.1146/annurev-clinpsy-081122-013201, PMID 38996077.
26. Bharathi K, Pugazhendhi K, Balamurugan K, Punithavathi D. Influence of duration of untreated psychosis on the short-term outcome in first-episode schizophrenia. Asian J Pharm Clin Res. 2024;17(5):152-5. doi: 10.22159/ajpcr.2024.v17i5.50217.
27. Klein HC, Guest PC, Dobrowolny H, Steiner J. Inflammation and viral infection as disease modifiers in schizophrenia. Front Psychiatry. 2023;14:1231750. doi: 10.3389/fpsyt.2023.1231750, PMID 37850104.
28. Fitton R, Sweetman J, Heseltine Carp W, Van Der Feltz Cornelis C. Anti-inflammatory medications for the treatment of mental disorders: a scoping review. Brain Behav Immun Health. 2022;26:100518. doi: 10.1016/j.bbih.2022.100518, PMID 36217374.
29. Sun X, Luo G, Li X, Wang J, Qiu Y, Li M. The relationship between inflammatory markers, clinical characteristics and cognitive performance in drug-naïve patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2024;274(6):1365-74. doi: 10.1007/s00406-023-01677-9, PMID 37902865.
30. Strube W, Aksar A, Bauer I, Barbosa S, Benros M, Blankenstein C. Effects of add-on celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized placebo-controlled trial. J Neural Transm (Vienna). 2023;130(8):1039-48. doi: 10.1007/s00702-022-02566-6, PMID 36401749.
31. Messina A, Concerto C, Rodolico A, Petralia A, Caraci F, Signorelli MS. Is it time for a paradigm shift in the treatment of schizophrenia? The use of inflammation-reducing and neuroprotective drugs a review. Brain Sci. 2023;13(6):957. doi: 10.3390/brainsci13060957, PMID 37371435.
32. Amerio A, Magnani L, Arduino G, Fesce F, De Filippis R, Parise A. Immunomodulatory effects of clozapine: more than just a side effect in schizophrenia. Curr Neuropharmacol. 2024;22(7):1233-47. doi: 10.2174/1570159X22666231128101725, PMID 38031778.
33. LV H, Guo M, Guo C, He K. The Interrelationships between cytokines and schizophrenia: a systematic review. Int J Mol Sci. 2024;25(15):8477. doi: 10.3390/ijms25158477, PMID 39126046.
34. Orbe EB. Towards biomarker-based personalized medicine in psychiatry: an individual-level participant data meta-analysis of anti-inflammatory add-on treatment for psychotic disorders. J Affect Disord Rep. 2023;12:100556. doi: 10.1016/j.jadr.2023.100556.
35. Karbalaee M, Jameie M, Amanollahi M, Taghavi Zanjani F, Parsaei M, Basti FA. Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophr Res. 2023;254:92-8. doi: 10.1016/j.schres.2023.02.020, PMID 36805834.
36. Guo L, Xiao P, Zhang X, Yang Y, Yang M, Wang T. Inulin ameliorates schizophrenia via modulation of the gut microbiota and anti-inflammation in mice. Food Funct. 2021;12(3):1156-75. doi: 10.1039/d0fo02778b, PMID 33432310.
37. Saleem A, Qurat-Ul-Ain MF, Akhtar MF. Alternative therapy of psychosis: potential phytochemicals and drug targets in the management of schizophrenia. Front Pharmacol. 2022;13:895668. doi: 10.3389/fphar.2022.895668, PMID 35656298.
38. Cha HY, Yang SJ. Anti-inflammatory diets and schizophrenia. Clin Nutr Res. 2020;9(4):241-57. doi: 10.7762/cnr.2020.9.4.241, PMID 33204665.
39. Suleiman M, Almalki FA, Ben Hadda T, Kawsar SM, Chander S, Murugesan S. Recent progress in synthesis, POM analyses and SAR of coumarin-hybrids as potential anti-HIV agents-a mini review. Pharmaceuticals (Basel). 2023;16(11):1538. doi: 10.3390/ph16111538, PMID 38004404.
40. Al-Maqtari HM, Hasan AH, Suleiman M, Ahmad Zahidi MA, Noamaan MA, Alexyuk P. Benzyloxychalcone hybrids as prospective acetylcholinesterase inhibitors against Alzheimer’s disease: rational design synthesis in silico ADMET prediction QSAR, molecular docking, DFT, and molecular dynamic simulation studies. ACS Omega. 2024;9(30):32901-19. doi: 10.1021/acsomega.4c03679, PMID 39100311.
41. Devaliya S, Tomar SP, Gupta P, Soni V, Dhakar JS. The unseen: burden in caregivers of patients with schizophrenia in a tertiary care institute. Asian J Pharm Clin Res. 2024;17(6):114-7. doi: 10.22159/ajpcr.2024.v17i6.50485.
42. Pandurangi AK, Buckley PF. Inflammation, antipsychotic drugs and evidence for effectiveness of anti-inflammatory agents in schizophrenia. Curr Top Behav Neurosci. 2020;44:227-44. doi: 10.1007/7854_2019_91, PMID 30993585.
43. Correll CU, Abi-Dargham A, Howes O. Emerging treatments in schizophrenia. J Clin Psychiatry. 2022;83(1):SU21024IP1. doi: 10.4088/JCP.SU21024IP1, PMID 35172048.
44. Vazova T, Vazov R, Radev V. Active aging among the elderly and its economic and social consequences in Bulgaria. Jur Ilmh Ilm Ter Un Ja. 2025;9(3):1037-54. doi: 10.22437/jiituj.v9i3.42957.
45. Abisheva S, Rutskaya Moroshan K, Nuranova G, Batyrkhan T, Abisheva A. Antimalarial drugs at the intersection of SARS-CoV-2 and rheumatic diseases: what are the potential opportunities? Medicina (Kaunas). 2024;60(7):1171. doi: 10.3390/medicina60071171, PMID 39064600.
46. Correll CU, Kim E, Sliwa JK, Hamm W, Gopal S, Mathews M. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39-59. doi: 10.1007/s40263-020-00779-5, PMID 33507525.
47. Adenekov SM, Kupriyanov AN, Turmukhambetov AZh, Gafurov NM, Dzhazin KA. Austricin from Artemisia juncea. Chem Nat Compd. 1992;28(6):633-4. doi: 10.1007/BF00630453.
48. Aliyarbayova A, Sultanova T, Yaqubova S, Najafova T, Sadiqova G, Salimova A. Macrophage migration inhibitory factor: its multifaceted role in inflammation and immune regulation across organ systems. Cell Physiol Biochem. 2025;59(5):569-88. doi: 10.33594/000000809, PMID 40916855.
49. Bogoyavlenskiy A, Zaitseva I, Alexyuk P, Alexyuk M, Omirtaeva E, Manakbayeva A. Naturally occurring isorhamnetin glycosides as potential agents against influenza viruses: antiviral and molecular docking studies. ACS Omega. 2023;8(50):48499-514. doi: 10.1021/acsomega.3c08407, PMID 38144046.
50. Mustafayeva K, Mahiou Leddet V, Suleymanov T, Kerimov Y, Ollivier E, Elias R. Chemical constituents from the roots of Cephalaria kotschyi. Chem Nat Compd. 2011;47(5):839-42. doi: 10.1007/s10600-011-0079-y.
51. Imanov E, Dziuryi IV, Truba IP, Golovenko OS. Experience of performing systemic-to-pulmonary artery shunt in patients with univentricular heart physiology and depleted pulmonary blood flow. UJCVS. 2024;32(2):74-9. doi: 10.30702/ujcvs/24.32(02)/ID034-7479.
52. Nurusheva SS, Abisheva ST, Abisheva AB, Kristina RM, Shaimerdenov SA. Late post-COVID syndrome: clinical complications beyong 12 w. J Clin Med Kaz. 2024;21(1):9-13. doi: 10.23950/jcmk/14268.
Published
How to Cite
Issue
Section
Copyright (c) 2026 ANDREI EFREMOV
This work is licensed under a Creative Commons Attribution 4.0 International License.